Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial
ConclusionThis study demonstrated the noninferiority of remogliflozin etabonate 100 and 250 mg compared with dapagliflozin, from the first analysis of an initial 612 patients. Remogliflozin etabonate therefore may be considered an effective and well-tolerated alternative treatment option for glycemic control in T2DM.Trial RegistrationCTRI/2017/07/009121.
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Dapagliflozin | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Drugs & Pharmacology | Electrocardiogram | Endocrinology | Fortamet | Forxiga | Fungal Infections | India Health | Laboratory Medicine | Metformin | Sodium | Study | Urinary Tract Infections